A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder Herschorn S, Barkin J, Castro-Diaz D, et al (Univ of Toronto, Ontario, Canada; Univ Hosp of the Canary Islands, Spain; Seattle Urology Res Ctr, Burien, WA; et al) Urology 82:313-320, 2013§

Publication date: 2014 Source:Yearbook of Urology, Volume 2014 Author(s): E.S. Rovner
Source: Yearbook of Urology - Category: Urology & Nephrology Source Type: research